ALK Positive Inc./LinkedIn
Jan 14, 2025, 18:08
New Research Highlight: Amivantamab With TKIs for Advanced NSCLC – ALK Positive Inc.
ALK Positive Inc. shared a post on LinkedIn:
“New Research Highlight: Amivantamab With TKIs for Advanced NSCLC.
Exciting advancements in lung cancer treatment are on the horizon! Researchers are now exploring the combination of Amivantamab with Tyrosine Kinase Inhibitors (TKIs) for advanced NSCLC patients with ALK, ROS1, or RET alterations for those progressing on their current targeted therapy.
Why is this important?
This combination therapy has the potential to enhance treatment outcomes for patients with specific genetic drivers of lung cancer, offering new hope for improved survival and quality of life.
More posts featuring ALK Positive Inc.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 11:28
Feb 22, 2025, 11:22
Feb 22, 2025, 11:15
Feb 22, 2025, 11:02
Feb 22, 2025, 10:47
Feb 22, 2025, 05:18